CELF4 and cardiomyopathy: In children exposed to >300 mg/m2 of anthracyclines, the rs1786814 GG homozygotes showed a 10.2-fold increased risk of cardiomyopathy as compared with the G/A or A/A genotypes, while carriers of the CELF4 rs1786814 A allele showed no change in risk of cardiomyopathy regardless of cumulative anthracycline exposure (66).